Have a feature idea you'd love to see implemented?
Let us know!
RIGL Rigel Pharmaceuticals Inc
Price (delayed)
$25.04
Market cap
$441.08M
P/E Ratio
100.16
Dividend/share
N/A
EPS
$0.25
Enterprise value
$449.62M
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare
Highlights
Rigel Pharmaceuticals's EPS has surged by 132% QoQ and by 118% YoY
The net income has surged by 127% since the previous quarter and by 116% year-on-year
The quick ratio has grown by 27% from the previous quarter but it has contracted by 5% YoY
The gross margin has contracted by 8% YoY and by 3.2% from the previous quarter
Key stats
What are the main financial stats of RIGL
Market
Valuations
Earnings
Shares outstanding
17.62M
Market cap
$441.08M
Enterprise value
$449.62M
Price to earnings (P/E)
100.16
Price to book (P/B)
N/A
Price to sales (P/S)
2.8
EV/EBIT
38.26
EV/EBITDA
32.9
EV/Sales
2.86
Revenue
$157.47M
EBIT
$11.75M
EBITDA
$13.67M
Free cash flow
$10.49M
Per share
Balance sheet
Liquidity
EPS
$0.25
Free cash flow per share
$0.6
Book value per share
-$0.83
Revenue per share
$8.95
TBVPS
$6.35
Total assets
$139.42M
Total liabilities
$154.06M
Debt
$60.23M
Equity
-$14.64M
Working capital
$52.16M
Debt to equity
-4.12
Current ratio
1.96
Quick ratio
1.69
Net debt/EBITDA
0.62
Margins
Efficiency
Dividend
EBITDA margin
8.7%
Gross margin
89.4%
Net margin
2.5%
Operating margin
6%
Return on assets
3%
Return on equity
N/A
Return on invested capital
17.5%
Return on capital employed
13.8%
Return on sales
7.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RIGL stock price
How has the Rigel Pharmaceuticals stock price performed over time
Intraday
3%
1 week
-8.81%
1 month
69.07%
1 year
176.99%
YTD
72.69%
QTD
54.76%
Financial performance
How have Rigel Pharmaceuticals's revenue and profit performed over time
Revenue
$157.47M
Gross profit
$140.83M
Operating income
$9.5M
Net income
$3.88M
Gross margin
89.4%
Net margin
2.5%
The operating margin has soared by 187% from the previous quarter and by 139% YoY
RIGL's operating income has surged by 147% year-on-year
The net income has surged by 127% since the previous quarter and by 116% year-on-year
RIGL's net margin has soared by 123% QoQ and by 114% YoY
Growth
What is Rigel Pharmaceuticals's growth rate over time
Valuation
What is Rigel Pharmaceuticals stock price valuation
P/E
100.16
P/B
N/A
P/S
2.8
EV/EBIT
38.26
EV/EBITDA
32.9
EV/Sales
2.86
Rigel Pharmaceuticals's EPS has surged by 132% QoQ and by 118% YoY
RIGL's equity has soared by 54% YoY and by 51% from the previous quarter
The stock's price to sales (P/S) is 56% more than its last 4 quarters average of 1.8 but 10% less than its 5-year quarterly average of 3.1
Rigel Pharmaceuticals's revenue has increased by 21% QoQ and by 19% YoY
Efficiency
How efficient is Rigel Pharmaceuticals business performance
RIGL's return on invested capital has surged by 170% year-on-year
Rigel Pharmaceuticals's return on sales has surged by 154% YoY
The return on assets has surged by 126% since the previous quarter and by 115% year-on-year
Dividends
What is RIGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RIGL.
Financial health
How did Rigel Pharmaceuticals financials performed over time
Rigel Pharmaceuticals's total assets is 10% less than its total liabilities
The quick ratio has grown by 27% from the previous quarter but it has contracted by 5% YoY
RIGL's current ratio is up by 21% since the previous quarter
RIGL's debt to equity has shrunk by 116% YoY and by 104% QoQ
RIGL's equity has soared by 54% YoY and by 51% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.